LE WE PMID CA
MTOR1849MTOR

Alcohol

Amino acid (Depletion)

AMP activated protein kinase

Antineoplastic agents (BASKET)

AP23573

ARF

Asparaginase

ATM

ATR

Autophagy

Biomembranes (Traffic)

Caveolin and caveoles

CCI779

CDC42

Cell migration

Cell Secretion (Exosomes)

Chmp4C

CNS (Neoplasia Glioblastoma)

DNA PK

DOCK2

DRAM

Endosom

Enzastaurin

Ephrin

Epilepsy (BASKET)

Epithelio mesenchymal transition

Everolimus

Farnesyl transferase

Fostamatinib

HIF1alpha und HIF1 (BASKET)

IGF1

IGFBP3

Immunopharmacology

Interferon alpha and preliminary (BASKET)

IQGAP1

Ischemia reperfusion

Kidney (Polycystic kidney disease)

Leukemia (acute myeloic)

Leukemia (chronic lymphatic)

LKB1

Lymphangioleiomyomatosis

Lymphoma (B cell diffuse large)

Lymphoma (BASKET)

MTOR

mTORC1

mTORC2

Muscle (Physiology)

Neoplasia (Invasion and metastasis)

Neoplasia (Tumor biology and immunology)

Nutrient sensing

Oxygen (Hypoxia)

P53

P70RSK

Pentose shunt

Perifosine ttPKB

Phosphatidic acid

Phospholipase D

PI3K

PIKK

PKD1

PKD2

PLD1

PLD2

Pmel17

Polycystin

Protein kinase B Akt

Protein kinase C beta

PTEN MMAC1 TEP1

PX866 ttPKB

RAD001 ttMTOR

Rapamycin

RHEB

Rho

Ridaforolimus ttMTOR

Sestrin1

Sestrin2

SMG1

Statin

Syk

Systemic lupus erythematosus

T cell (BASKET)

Temsirolimus

TGF beta

TSAP6

TSC1 Hamartin

TSC2 Tuberin

Tuberculosis

Ubiquitin

Unfolded protein response

Virus (BASKET)

Virus (DNA Virus)

Warburg effect

Wound healing

2005  
1
Signaling by target of rapamycin proteins in cell growth control.
[15755954] Microbiol Mol Biol Rev 69(1): 79-100 (2005)
2008  
2
Rapamycin and mTOR kinase inhibitors.
[19568796] J Chem Biol 1(1-4): 27-36 (2008)
2005  
3
The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
[16217558] Cell Mol Biol Lett 10(3): 479-98 (2005)
2007  
4
2009  
5
Coordination of Ribosomal Protein and Ribosomal RNA Gene Expression in Response to TOR Signaling.
[19881913] Curr Genomics 10(3): 198-205 (2009)
2009  
6
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.
[19381454] Target Oncol 4(2): 135-42 (2009)
2008  
7
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies.
[18566209] Mol Cancer Ther 7(6): 1347-54 (2008)
2005  
8
mTOR-targeted therapy of cancer with rapamycin derivatives.
[15728109] Ann Oncol 16(4): 525-37 (2005)
2007  
9
The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.
[17545512] Clin Cancer Res 13(11): 3109-14 (2007)
2007  
10
The biology behind mTOR inhibition in sarcoma.
[17766661] Oncologist 12(8): 1007-18 (2007)
2004  
11
Upstream and downstream of mTOR.
[15314020] Genes Dev 18(16): 1926-45 (2004)
2007  
12
Defining the role of mTOR in cancer.
[17613433] Cancer Cell 12(1): 9-22 (2007)
2006  
13
TOR signaling in growth and metabolism.
[16469695] Cell 124(3): 471-84 (2006)
2001  
14
Microtubules, motors, and mRNA localization mechanisms: watching fluorescent messages move.
[11747806] Cell 107(6): 707-10 (2001)
2000  
15
TOR, a central controller of cell growth.
[11057898] Cell 103(2): 253-62 (2000)
2005  
16
TOR signaling: an odyssey from cellular stress to the cell growth machinery.
[15723787] Curr Biol 15(4): R139-41 (2005)
2006  
17
The amino acid sensitive TOR pathway from yeast to mammals.
[16684541] FEBS Lett 580(12): 2821-9 (2006)
2010  
18
2006  
19
Therapeutic targets: MTOR and related pathways.
[16969122] Cancer Biol Ther 5(9): 1065-73 (2006)
2003  
20
The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
[14508096] Cancer Biol Ther 2(4 Suppl 1): S169-77 (2003)
2009  
21
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.
[19245654] Acta Physiol (Oxf) 196(1): 65-80 (2009)
2009  
22
2009  
23
Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.
[19264150] Biochim Biophys Acta 1791(9): 949-55 (2009)
2010  
24
Eph receptor and mTOR pathway crosstalk: implications for cancer.
[20505333] Cell Cycle 9(11): 2053-4 (2010)
2006  
25
Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair?
[17102641] Cell Cycle 5(21): 2425-9 (2006)
2010  
26
Reduced mortality and moderate alcohol consumption: the phospholipase D-mTOR connection.
[20372065] Cell Cycle 9(7): 1291-4 (2010)
2008  
27
2008  
28
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors.
[19098454] Cell Cycle 7(24): 3805-9 (2008)
2007  
29
All roads lead to mTOR: integrating inflammation and tumor angiogenesis.
[18073529] Cell Cycle 6(24): 3011-4 (2007)
2006  
30
The mTOR pathway in the control of protein synthesis.
[16990457] Physiology (Bethesda) 21(-): 362-9 (2006)
2010  
31
Of mice and men: therapeutic mTOR inhibition in polycystic kidney disease.
[20133481] J Am Soc Nephrol 21(3): 390-1 (2010)
2009  
32
The role of the mammalian target of rapamycin (mTOR) in renal disease.
[19875810] J Am Soc Nephrol 20(12): 2493-502 (2009)
2010  
33
Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
[20160148] Proc Am Thorac Soc 7(1): 48-53 (2010)
2009  
34
2010  
35
Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony.
[20231296] J Biol Chem 285(19): 14071-7 (2010)
2010  
36
New concepts in phospholipase D signaling in inflammation and cancer.
[20623096] ScientificWorldJournal 10(-): 1356-69 (2010)
2010  
37
An emerging role for IQGAP1 in regulating protein traffic.
[20495773] ScientificWorldJournal 10(-): 944-53 (2010)
2011  
38
Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery: drug discovery for targeting the tumor microenvironment.
[21422725] J Pharmacol Sci 115(4): 446-52 (2011)
2010  
39
Signal transduction inhibitor therapy for lymphoma.
[21239804] Hematology Am Soc Hematol Educ Program 2010(-): 265-70 (2010)
2010  
40
mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?
[20350481] Discov Med 9(46): 173-8 (2010)
2010  
41
TOR-dependent control of autophagy: biting the hand that feeds.
[20006481] Curr Opin Cell Biol 22(2): 157-68 (2010)
2011  
42
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.
[21490404] J Clin Invest 121(4): 1231-41 (2011)
2010  
43
p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment.
[20182617] Cold Spring Harb Perspect Biol 2(2): a001057 (2010)
2011  
44
Regulation of autophagy by lysosomal positioning.
[21521941] Autophagy 7(8): 927-8 (2011)
2008  
45
The role of TOR in autophagy regulation from yeast to plants and mammals.
[18670193] Autophagy 4(7): 851-65 (2008)
2010  
46
mTOR regulation of autophagy.
[20083114] FEBS Lett 584(7): 1287-95 (2010)
2004  
47
Mammalian target of rapamycin inhibition.
[15448035] Clin Cancer Res 10(18 Pt 2): 6382S-7S (2004)
2004  
48
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
[14770419] Cancer 100(4): 657-66 (2004)
2007  
49
Regulation of mTOR by phosphatidic acid?
[17210675] Cancer Res 67(1): 1-4 (2007)
2004  
50
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer.
[15365568] Br J Cancer 91(8): 1420-4 (2004)
2010  
51
Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.
[20498248] Clin J Am Soc Nephrol 5(7): 1312-29 (2010)
2011  
52
Targeting mTOR for the treatment of AML. New agents and new directions.
[21680954] Oncotarget 2(6): 510-7 (2011)
2010  
53
The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein.
[20399660] Trends Cell Biol 20(7): 427-34 (2010)
2009  
54
Immunoregulatory functions of mTOR inhibition.
[19390566] Nat Rev Immunol 9(5): 324-37 (2009)
2010  
55
With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging.
[20519118] Cell Metab 11(6): 453-65 (2010)
2012  
56
Ubiquitin-proteasome system inhibitors and AMPK regulation in hepatic cold ischaemia and reperfusion injury: possible mechanisms.
[22455352] Clin Sci (Lond) 123(2): 93-8 (2012)
2011  
57
Rheb/mTOR activation and regulation in cancer: novel treatment strategies beyond rapamycin.
[21561413] Curr Drug Targets 12(8): 1223-31 (2011)
2009  
58
Akt-dependent and -independent mechanisms of mTOR regulation in cancer.
[19166931] Cell Signal 21(5): 656-64 (2009)
2009  
59
Common mechanisms of PIKK regulation.
[19464237] DNA Repair (Amst) 8(9): 1004-8 (2009)
2010  
60
mTOR signaling: at the crossroads of plasticity, memory and disease.
[19963289] Trends Neurosci 33(2): 67-75 (2010)
2009  
61
Dysregulation of the mTOR pathway secondary to mutations or a hostile microenvironment contributes to cancer and poor wound healing.
[19209152] J Invest Dermatol 129(3): 529-31 (2009)
2009  
62
Targeting mTOR-dependent tumours with specific inhibitors: a model for personalized medicine based on molecular diagnoses.
[19229373] Curr Oncol 16(1): 59-61 (2009)
2009  
63
Targeting the mTOR signaling network for cancer therapy.
[19332717] J Clin Oncol 27(13): 2278-87 (2009)
2010  
64
Targeted therapy in lymphoma.
[21092307] J Hematol Oncol 3(-): 45 (2010)
2009  
65
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.
[19860903] J Hematol Oncol 2(-): 45 (2009)
2011  
66
Mammalian target of rapamycin: a central node of complex signaling cascades.
[21738819] Int J Clin Exp Pathol 4(5): 476-95 (2011)
2009  
67
2008  
68
Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.
[18440854] Drug Resist Updat 11(3): 63-76 (2008)
2008  
69
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.
[18166498] Drug Resist Updat 11(1-2): 32-50 (2008)
2011  
70
Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-β-induced epithelial-mesenchymal transition.
[21041997] Cells Tissues Organs 193(1-2): 8-22 (2011)
2009  
71
Mechanisms of amino acid sensing in mTOR signaling pathway.
[20016704] Nutr Res Pract 3(1): 64-71 (2009)
2009  
72
Emerging evidence of a link between the polycystins and the mTOR pathways.
[19863783] Pathogenetics 2(1): 6 (2009)
2008  
73
Regulation of mTOR signaling in skeletal muscle hypertrophy.
[19147966] J Musculoskelet Neuronal Interact 8(4): 338-9 (2008)
2010  
74
mTOR signaling in glioblastoma: lessons learned from bench to bedside.
[20472883] Neuro Oncol 12(8): 882-9 (2010)
2010  
75
Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
[19817806] Epilepsia 51(1): 27-36 (2010)
2011  
76
The functions of mTOR in ischemic diseases.
[21871173] BMB Rep 44(8): 506-11 (2011)
2010  
77
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy.
[20418915] Oncogene 29(26): 3733-44 (2010)
2010  
78
Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway.
[20661228] Lab Invest 90(10): 1406-14 (2010)
2008  
79
The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway.
[18311165] Nat Rev Microbiol 6(4): 266-75 (2008)
2010  
80
mTOR signaling in cancer cell motility and tumor metastasis.
[20528734] Crit Rev Eukaryot Gene Expr 20(1): 1-16 (2010)
2010  
81
The role of chemokines in migration of metastatic-like lymphangioleiomyomatosis cells.
[20666708] Crit Rev Immunol 30(4): 387-94 (2010)
2009  
82
mTOR: dissecting regulation and mechanism of action to understand human disease.
[19143634] Biochem Soc Trans 37(Pt 1): 213-6 (2009)
2009  
83
A complex interplay between Akt, TSC2 and the two mTOR complexes.
[19143635] Biochem Soc Trans 37(Pt 1): 217-22 (2009)
2010  
84
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress.
[20965424] Mol Cell 40(2): 310-22 (2010)
2010  
85
Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.
[21307646] Oxid Med Cell Longev 3(6): 374-91 (2010)
2011  
86
Frontier of epilepsy research - mTOR signaling pathway.
[21467839] Exp Mol Med 43(5): 231-74 (2011)
2010  
87
The complexes of mammalian target of rapamycin.
[20491627] Curr Protein Pept Sci 11(6): 409-24 (2010)
2010  
88
Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.
[20535652] Curr Top Microbiol Immunol 347(-): 279-96 (2010)
2010  
89
The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism.
[20870173] Immunity 33(3): 301-11 (2010)
2010  
90
A comprehensive map of the mTOR signaling network.
[21179025] Mol Syst Biol 6(): 453 (2010)
2011  
91
mTOR: from growth signal integration to cancer, diabetes and ageing.
[21157483] Nat Rev Mol Cell Biol 12(1): 21-35 (2011)
PMC   
92
Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema.
[20473305] Nat Med 16(7):767-73 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



Search PubMed and many other databases on the combined search terms

GG: mtor
GG: mtorc
GG: mtorc1
GG: mtorc2

  • MTOR

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia